Our Pricing

Mounjaro Clicks Chart Safety: What Side Effects to Expect

Published on: June 03, 2026

Understanding the mounjaro clicks chart side effects UK is essential before starting tirzepatide treatment. At Cured Pharmacy, we provide transparent guidance on Mounjaro's dosing system, helping you recognise what to expect at each click level. Mounjaro is available from £124.99 following a free online consultation with our UK-registered prescribers.

Understanding the Mounjaro Clicks Chart System

The Mounjaro KwikPen uses a clicks-based dosing system where each click corresponds to a specific dose of tirzepatide. The pen is pre-filled and delivers doses ranging from 2.5mg to 15mg, with the number of clicks varying by prescribed strength [1]. This system ensures accurate dosing without requiring patients to measure liquid volumes.

Your UK prescriber will determine your starting dose based on your medical history and weight loss goals. The MHRA-approved dosing schedule typically begins at 2.5mg weekly for four weeks, then escalates gradually to minimise gastrointestinal side effects [1]. Each dose increase allows your body to adapt to higher tirzepatide levels, improving tolerability.

The clicks chart provided with your Mounjaro pen shows exactly how many clicks deliver your prescribed dose. For example, the 2.5mg pen requires 2 clicks, whilst the 5mg pen requires 4 clicks. Never adjust the number of clicks without consulting your prescriber, as incorrect dosing may increase side effect risk or reduce efficacy.

Common Mounjaro Side Effects by Dose Level

Clinical trials show that side effects correlate with dose escalation, with gastrointestinal symptoms being most common during the first few weeks after increasing your dose [2]. In the SURPASS-1 trial, nausea occurred in 12-20% of patients depending on dose, whilst diarrhoea affected 12-16% [2]. These effects typically diminish as your body adjusts to each new dose level.

At the starting 2.5mg dose, most patients experience mild or no side effects. The most frequently reported symptoms include slight nausea, reduced appetite, and occasional indigestion. These effects are generally well-tolerated and rarely lead to treatment discontinuation at this dose [2].

As doses increase to 5mg, 7.5mg, and beyond, gastrointestinal side effects become more pronounced but remain manageable for most patients. Approximately 5-7% of trial participants discontinued tirzepatide due to adverse effects, primarily nausea and vomiting [2]. Eating smaller, more frequent meals and avoiding high-fat foods can significantly reduce symptom severity.

Managing Side Effects During Dose Escalation

Your UK prescriber may recommend staying at a lower dose for an additional four weeks if you experience persistent side effects. This flexible approach, supported by NICE guidance, allows individualised treatment whilst maintaining efficacy [3]. Never skip doses or alter your schedule without clinical guidance, as this may compromise treatment outcomes.

Serious Side Effects and Safety Monitoring

Whilst most Mounjaro side effects are mild and transient, rare serious reactions require immediate medical attention. These include severe abdominal pain that may indicate pancreatitis, symptoms of thyroid tumours (neck lump, difficulty swallowing), or signs of gallbladder disease [1][4]. The MHRA requires prescribers to screen for personal or family history of medullary thyroid carcinoma before initiating tirzepatide.

Hypoglycaemia (low blood sugar) is uncommon with Mounjaro monotherapy but may occur if you're taking other diabetes medications concurrently. Symptoms include trembling, sweating, confusion, and rapid heartbeat [4]. Your prescriber will assess your full medication list during consultation to minimise this risk.

Allergic reactions to tirzepatide are rare but can manifest as rash, itching, dizziness, or difficulty breathing. If you experience these symptoms, stop injecting and seek emergency medical care immediately. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures all dispensed Mounjaro pens meet UK licensing standards and include comprehensive patient information leaflets.

Mounjaro Side Effects Compared to Other Weight Loss Treatments

Compared to semaglutide-based treatments like Wegovy, tirzepatide demonstrates a similar side effect profile but with potentially greater weight loss efficacy. In head-to-head comparisons, tirzepatide produced average weight reductions of 22.5% versus 14.9% for semaglutide, with comparable gastrointestinal tolerability [1][5].

Orlistat-based treatments such as Xenical cause different side effects, primarily gastrointestinal issues related to fat malabsorption rather than appetite suppression. Patients often report oily stools, flatulence, and urgent bowel movements with orlistat, which differ significantly from the nausea and reduced appetite seen with GLP-1 receptor agonists [6].

The dual GIP/GLP-1 mechanism of Mounjaro may offer advantages in side effect management. GIP receptor activation appears to counterbalance some GLP-1-related nausea in preclinical models, potentially explaining why some patients tolerate tirzepatide better than single-pathway alternatives [1].

Choosing Between Injectable and Oral Options

Wegovy oral tablets, now available for pre-order at Cured Pharmacy, offer an alternative for patients who prefer not to inject. However, oral semaglutide requires specific administration instructions (taken on an empty stomach with minimal water) and may have different side effect timing compared to weekly injections. Your UK prescriber will discuss which formulation best suits your lifestyle and medical needs.

Long-Term Safety Data and Monitoring Requirements

The SURPASS clinical trial programme followed patients for up to 72 weeks, providing robust long-term safety data for tirzepatide [2]. Cardiovascular outcomes studies are ongoing, with preliminary data suggesting neutral to beneficial effects on heart health markers including blood pressure and lipid profiles.

UK prescribers typically recommend monitoring appointments every 3-6 months whilst on Mounjaro. These reviews assess weight loss progress, side effect management, and any changes in your overall health status. Blood tests may be requested to monitor kidney function, liver enzymes, and HbA1c if you have concurrent diabetes [3].

The MHRA continues post-marketing surveillance of all GLP-1 receptor agonists, including tirzepatide. Healthcare professionals report suspected adverse reactions through the Yellow Card scheme, ensuring ongoing safety monitoring. At Cured Pharmacy, we maintain comprehensive patient records and coordinate with your GP where appropriate to ensure continuity of care.

Accessing Mounjaro Safely Through UK Pharmacies

Mounjaro is a prescription-only medication in the UK and cannot be legally supplied without clinical assessment by a UK-registered prescriber. At Cured Pharmacy (GPhC Registration Number 9012511), our online consultation takes under three minutes and is reviewed by qualified UK clinicians who assess your suitability for tirzepatide treatment.

We provide transparent upfront pricing with Mounjaro available from £124.99 significantly lower than typical market rates. All medicines are sourced directly from UK-licensed wholesalers and dispensed by our registered pharmacy team. We guarantee 100% discreet packaging with next-day delivery options available across the UK.

Your Mounjaro prescription includes comprehensive patient information covering the clicks chart system, side effect management, and emergency contact guidance. Our pharmacy team remains available on (+44) 116 4646009 for any questions about your treatment. All prescription medications require ongoing clinical oversight, and we coordinate repeat prescriptions seamlessly through your online account.

Starting Your Mounjaro Treatment Journey

Begin by completing our free online consultation, where you'll provide medical history details including current medications, allergies, and weight loss goals. Our UK prescribers review every consultation individually, ensuring Mounjaro is clinically appropriate and safe for you. If approved, your prescription is sent directly to our pharmacy for same-day dispensing, with discreet delivery to your chosen address.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes [TA924]. NICE. https://www.nice.org.uk/guidance/ta924 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. https://products.mhra.gov.uk/ [accessed 13 August 2026]
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
6. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro side effects vary between individuals, and this guide does not replace personalised medical advice from your prescriber.